| Recruiting | A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2 NCT06329999 | Ruijin Hospital | N/A |
| Recruiting | CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia NCT05672147 | City of Hope Medical Center | Phase 1 |
| Terminated | Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After NCT03537599 | Sumithira Vasu | Phase 1 / Phase 2 |
| Active Not Recruiting | Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute NCT03513484 | Northwestern University | Phase 1 |
| Terminated | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acu NCT03519984 | University of Southern California | Phase 1 |
| Withdrawn | Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults NCT02791919 | National Cancer Institute (NCI) | Phase 1 |
| Completed | WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or NCT02666950 | Mayo Clinic | Phase 2 |
| Completed | Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia NCT02581917 | Wake Forest University Health Sciences | — |
| Terminated | Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic NCT03146871 | University of Southern California | Phase 2 |
| Recruiting | A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemi NCT03017820 | Mayo Clinic | Phase 1 |
| Completed | Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS NCT02921061 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT02635074 | Steven E. Coutre | Phase 1 |
| Recruiting | Personalized NK Cell Therapy in CBT NCT02727803 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HS NCT02728700 | Stanford University | Phase 1 |
| Completed | Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations NCT02323607 | Bhavana Bhatnagar | Phase 1 |
| Active Not Recruiting | Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT02159495 | City of Hope Medical Center | Phase 1 |
| Completed | Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Mye NCT02583893 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Mye NCT02484391 | Wake Forest University Health Sciences | Phase 1 |
| Terminated | Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies NCT02381548 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hema NCT02122081 | Sumithira Vasu | Phase 1 |
| Completed | Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelo NCT02446964 | City of Hope Medical Center | Phase 1 |
| Terminated | Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT02337478 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT02299518 | Alice Mims | Phase 1 |
| Completed | Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute NCT02316964 | Sumithira Vasu | Phase 1 |
| Terminated | Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML NCT01849276 | Northwestern University | Phase 1 |
| Suspended | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With R NCT02333162 | University of Chicago | Phase 1 |
| Terminated | MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloi NCT02049801 | Bruno C. Medeiros | Phase 1 |
| Terminated | Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia NCT02353143 | Menarini Group | Phase 1 |
| Completed | Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Ac NCT02070458 | Case Comprehensive Cancer Center | Phase 1 |
| Completed | A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leuk NCT02204085 | Beth Israel Deaconess Medical Center | Phase 1 / Phase 2 |
| Completed | Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01787474 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or NCT02094794 | City of Hope Medical Center | Phase 2 |
| Completed | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies NCT02129101 | Mayo Clinic | Phase 1 |
| Completed | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in NCT01858740 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT02030405 | Steven E. Coutre | Phase 2 |
| Completed | CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome NCT02019069 | Rondeep Brar | Phase 2 |
| Terminated | Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leuke NCT01904643 | Stanford University | Phase 1 |
| Terminated | AML Therapy With Irradiated Allogeneic Cells NCT02105116 | Rutgers, The State University of New Jersey | N/A |
| Completed | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed o NCT02044796 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Maligna NCT01652014 | University of Medicine and Dentistry of New Jersey | Phase 2 |
| Terminated | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia NCT01907815 | National Cancer Institute (NCI) | Phase 2 |
| Completed | AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia NCT01798901 | Alison Walker | Phase 1 |
| Terminated | Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia NCT01876953 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay NCT01872819 | University of Washington | N/A |
| Completed | Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukem NCT01869114 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Active Not Recruiting | Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia NCT01861314 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hemato NCT01789255 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treatin NCT01707004 | University of Wisconsin, Madison | Phase 2 |
| Completed | Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01664897 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01835288 | Stanford University | Phase 2 |
| Completed | Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia NCT01870596 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01820624 | Paolo Caimi, MD | Phase 1 |
| Completed | PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant NCT01841333 | University of Colorado, Denver | Phase 2 |
| Completed | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01839916 | University of Chicago | Phase 2 |
| Terminated | Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia NCT01801046 | University of Southern California | Phase 1 |
| Completed | CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Mye NCT01768897 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies NCT01760655 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapse NCT01729845 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloi NCT01757639 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplasti NCT01640301 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Unknown | Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) A NCT01758367 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015 | City of Hope Medical Center | Phase 1 |
| Completed | Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With NCT01519596 | Wake Forest University Health Sciences | N/A |
| Completed | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell NCT01527045 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS NCT01607645 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leuk NCT01839240 | University of Chicago | Phase 1 |
| Withdrawn | Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia NCT01548911 | Wake Forest University Health Sciences | Phase 2 |
| Terminated | Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT01550185 | Roswell Park Cancer Institute | Phase 1 |
| Withdrawn | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant NCT01558778 | Roswell Park Cancer Institute | N/A |
| Completed | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem NCT01529827 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With NCT01300572 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies NCT01523223 | Robert Lowsky | Phase 1 |
| Completed | Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia NCT01555268 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies NCT01564277 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Trans NCT01427881 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies NCT01384513 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemother NCT01307579 | Children's Oncology Group | Phase 3 |
| Terminated | Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed NCT01342887 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01246622 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Re NCT01249430 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766 | Wake Forest University Health Sciences | Phase 2 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Terminated | Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute My NCT01260714 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previ NCT01235572 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01253447 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Tran NCT01233921 | Martin, Paul | N/A |
| Completed | Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia NCT01174888 | Alison Walker | Phase 1 |
| Completed | Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacit NCT01168219 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia NCT01127009 | Case Comprehensive Cancer Center | Phase 1 |
| Terminated | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload NCT01159067 | City of Hope Medical Center | Phase 2 |
| Completed | Veliparib and Temozolomide in Treating Patients With Acute Leukemia NCT01139970 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory NCT01159301 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS NCT01159028 | Bio-Path Holdings, Inc. | Phase 1 |
| Terminated | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Bloo NCT01076270 | Fred Hutchinson Cancer Center | N/A |
| Completed | Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01130506 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia NCT01132586 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High- NCT00988715 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or A NCT01083706 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer NCT01044745 | University of Nebraska | Phase 2 |
| Completed | 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodyspl NCT01041443 | City of Hope Medical Center | Phase 1 |
| Completed | Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Pr NCT01031368 | Nohla Therapeutics, Inc. | Phase 1 |
| Completed | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML NCT00895934 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Pa NCT00860574 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease NCT00863434 | University of Washington | Phase 2 |
| Completed | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With NCT00856388 | Roswell Park Cancer Institute | N/A |
| Completed | Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia NCT02144675 | Rutgers, The State University of New Jersey | Phase 2 |
| Completed | Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS NCT00839982 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory A NCT00634244 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant NCT00795769 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors NCT00799461 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Phase 3 |
| Completed | Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia NCT00703300 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High- NCT00475150 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary NCT00666588 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leu NCT00588991 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT00602225 | University of Washington | Phase 1 / Phase 2 |
| Completed | Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia NCT00588809 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01093586 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treat NCT00540995 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia NCT00470197 | National Cancer Institute (NCI) | Phase 1 |
| Completed | MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myelo NCT00462605 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplast NCT00459212 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, NCT00445744 | Fred Hutchinson Cancer Center | N/A |
| Active Not Recruiting | Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia NCT00392353 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Sunitinib in Treating Patients With Idiopathic Myelofibrosis NCT00387426 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonoc NCT00313586 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Ph NCT00383474 | National Cancer Institute (NCI) | Phase 1 |
| Completed | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in T NCT00536601 | Roswell Park Cancer Institute | N/A |
| Completed | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem NCT00408681 | Fred Hutchinson Cancer Center | N/A |
| Completed | Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer NCT00357708 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases NCT00351975 | National Cancer Institute (NCI) | Phase 1 |
| Completed | PXD101 in Treating Patients With Acute Myeloid Leukemia NCT00357032 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or M NCT00357305 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrom NCT00331513 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgki NCT00275080 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myeloge NCT00278330 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat in Treating Patients With Acute Myeloid Leukemia NCT00305773 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With NCT00322101 | Fred Hutchinson Cancer Center | Phase 3 |
| Terminated | SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Ph NCT00301769 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic NCT00301938 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blast NCT00217646 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemi NCT00131989 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hemat NCT00103272 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofe NCT00118352 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic NCT00098826 | National Cancer Institute (NCI) | Phase 1 |
| Completed | MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, o NCT00101179 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lym NCT00098423 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease i NCT00105001 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT00101296 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leuk NCT00101231 | National Cancer Institute (NCI) | Phase 1 |
| Completed | XK469R in Treating Patients With Refractory Hematologic Cancer NCT00095797 | National Cancer Institute (NCI) | Phase 1 |
| Completed | S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia NCT00093418 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Tran NCT01056614 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission NCT00093470 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic S NCT00087204 | National Cancer Institute (NCI) | Phase 1 |
| Completed | CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, NCT00084916 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previo NCT00079378 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies NCT00077181 | National Cancer Institute (NCI) | Phase 1 |
| Completed | GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia NCT00070551 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT00062075 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Trans NCT00119366 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor He NCT00068718 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer NCT00060372 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Le NCT00052598 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia NCT00049582 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leuke NCT00052520 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leuke NCT00039091 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation NCT00040846 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Tr NCT00027820 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acut NCT00017472 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer NCT00012376 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia NCT00016016 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Imm NCT00014235 | Fred Hutchinson Cancer Center | N/A |
| Completed | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporin NCT00006251 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia NCT00006213 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initi NCT00005942 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, NCT00005064 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients Wi NCT00005799 | Fred Hutchinson Cancer Center | N/A |
| Completed | Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed NCT00008177 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating NCT00003875 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patient NCT01177371 | Case Comprehensive Cancer Center | Phase 2 |
| Approved For Marketing | Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyel NCT01869803 | Wake Forest University Health Sciences | — |